Rare Biomarkers Specimen Collection and Stabilization Market

Global Rare Biomarkers Specimen Collection and Stabilization Market By Product (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Types (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles), Specimens (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA (Ribonucleic Acid), DNA (Deoxyribonucleic Acid), and Others), Applications (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), By End-users (Research [Research Labs/CROs and Academic Institutes], and Diagnostics [Laboratories, Hospitals, and Prenatal Clinics]), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-3946
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 165
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global rare disease genetic testing market size was valued at USD 26.3 billion in the year 2020 and is expected to reach USD 48.5 billion by 2028 expanding at a CAGR of 9.2% during the forecast period, 2021–2028. The key drivers of this market are increased research initiatives to depict the significance of circulating biomarkers in disease treatment, as well as rising demand for non-invasive cancer diagnostic and tailored therapies.

Rare Biomarkers Specimen Collection and Stabilization Market key takeaways

The number of research projects has expanded dramatically in recent years. The growing quantity of scientific papers on these rare biomarker specimen collection and stabilization methods reflects healthcare organizations' growing interest in this market. Furthermore, growing evidence of uncommon biomarkers' efficacy in illness management has prompted investments in clinical applications. Researchers are embracing increasingly sensitive, quick, and flexible analytical technologies because of the promise of circulating biomarkers as high-value medication delivery systems and possible diagnostics. To enhance research possibilities, key firms are creating novel technologies and solutions for the collection and stability of these uncommon biomarkers specimens. Despite a slew of benefits, there are still obstacles to overcome in terms of practical application.

Market Trends, Drivers, Restraints, and Opportunities:

  • Introduction of liquid biopsy for cancer management has had a significant impact on the market dynamics for uncommon biomarker specimen collection and stabilization tubes.
  • Companies implementing or developing liquid biopsy are recognized as one of the leading drivers in the market for collecting and stabilizing rare biomarker specimens.
  • Growing demand for accurate and appropriate diagnoses for rare diseases is projected to have a significant impact on the market.
  • Regulatory challenges and limited refunds act as key factors that can restrict the market expansion during the forecast period.
  • Lack of skilled healthcare workers in emerging economies possess as major challenges that can hinder the market growth in the coming years.
  • Technological advancements in biomarker isolation are estimated to create opportunities for market players.
  • Increasing initiatives for exosome research by various government and non-government organization is expected to create growth opportunity for key players.

Scope of the Report

The report on the global rare disease genetic testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes                                      

Details

Report Title

Rare Biomarkers Specimen Collection and Stabilization Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Product (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Types (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles), Specimens (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA (Ribonucleic Acid), DNA (Deoxyribonucleic Acid), and Others), Applications (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), By End-users (Research [Research Labs/CROs and Academic Institutes], and Diagnostics [Laboratories, Hospitals, and Prenatal Clinics])

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered

Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc., ApoCell, Inc., AS One InternationalNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., Caltag Medsystems Limited, Cytomark Ltd., DNA Genotek, Inc., Epic Sciences, EpiGentek Group Inc., F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Geno Technology Inc., Genomax Technologies Pvt Ltd., and GILUPI GmbH

 

Global Rare Disease Genetic Testing Market Segment Insights

The blood collection segment is anticipated to hold major market share

Based on product, the market is divided into isolation kits & reagents, blood collection tubes, and systems. The blood collection tubes segment is anticipated to hold significant market share during the forecast period. Increasing number of surgeries due to various conditions and accidents is expected to drive the blood collection tubes segment in the coming years.

Rare Biomarkers Specimen Collection and Stabilization Market  by products

The circulating tumor cells segment is estimated to grow at a rapid pace

In term of types, the rare biomarkers specimen collection and stabilization market is segregated into circulating cell free DNA (ccfDNA), circulating tumor cells (CTCs), and exosomes/extracellular vesicles. The circulating tumor cells (CTCs) segment is estimated to expand at a rapid pace during the forecast period. Circulating tumor cells (CTCs) are a rare group of cells identified in the blood of solid tumor patients that serve as a seed for metastasis.

The serum/plasma segment is anticipated to expand at a high CAGR

Based on specimen, the rare biomarkers specimen collection and stabilization market is divided into serum/plasma, and others. The serum/plasma segment is anticipated to expand at a high CAGR during the forecast period. Serum/plasma is derived from the liquid portion of the blood that remains after the cells have been removed. The liquid that remains after the blood has clots is known as serum. When clotting is stopped with the use of an anticoagulant, the liquid that remains is called plasma.

The RNA segment is expected to hold a major market share

On the basis of nucleic acid & other biomolecules, the rare biomarkers specimen collection and stabilization market is segmented into RNA, DNA, and others. The RNA segment is expected to hold a major market share. Ribonucleic acid (RNA) is a polymeric molecule that plays a variety of roles in biology, including gene coding, decoding, regulation, and expression.

The oncology segment is grow at a substantial rate

Based on application, the rare biomarkers specimen collection and stabilization market is segregated into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. The oncology segment is expected to hold substantial market share during the forecast period owing to raising various government and non-government initiatives to curb the occurrence of cancer diseases.

Rare Biomarkers Specimen Collection and Stabilization Market by applications

North America is anticipated to dominate the market

On the basis of regions, the global immune health supplements market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market. The presence of large client base, as well as a large number of FDA authorized products in the region, is key factors driving the market. Furthermore, with the growing need for liquid biopsy and assisted reproductive technologies in the region, the number of approved isolation kits for clinical and research usage is expected to rise.

Segments

Segments Covered in the Report:

By Product

  • Isolation Kits & Reagents
  • Blood Collection Tubes
  • Systems
By Types
  • Circulating Call Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Extracellular Vesicles
By Specimen
  • Serum/Plasma
  • Others
By Nucleic Acid & Other Biomolecules
  • RNA (Ribonucleic Acid)
  • DNA (Deoxyribonucleic Acid)
  • Others
By Application
  • NIPT
  • Oncology
  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Cardiovascular
  • Diseases
  • Others
By Regions
  • Asia Pacific
  • North America
  • Europe
  • Latin America
  • Middle East & Africa
By Key Players
  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc.
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pvt Ltd.
  • GILUPI GmbH

Competitive Landscape

Some of the key players in the rare disease genetic testing market include Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc., ApoCell, Inc., AS One InternationalNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., Caltag Medsystems Limited, Cytomark Ltd., DNA Genotek, Inc., Epic Sciences, EpiGentek Group Inc., F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Geno Technology Inc., Genomax Technologies Pvt Ltd., and GILUPI GmbH.

Rare Biomarkers Specimen Collection and Stabilization Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rare Biomarkers Specimen Collection and Stabilization Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Rare Biomarkers Specimen Collection and Stabilization Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Rare Biomarkers Specimen Collection and Stabilization Market - Supply Chain
  4.5. Global Rare Biomarkers Specimen Collection and Stabilization Market Forecast
     4.5.1. Rare Biomarkers Specimen Collection and Stabilization Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Rare Biomarkers Specimen Collection and Stabilization Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Rare Biomarkers Specimen Collection and Stabilization Market Absolute $ Opportunity
5. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     5.3.1. Circulating Call Free DNA (ccfDNA)
     5.3.2. Circulating Tumor Cells (CTCs)
     5.3.3. Exosomes/Extracellular Vesicles
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     6.3.1. NIPT
     6.3.2. Oncology
     6.3.3. Transcriptomics
     6.3.4. Pharmacogenomics
     6.3.5. Transplant Rejection
     6.3.6. Population Screening
     6.3.7. Cardiovascular
     6.3.8. Diseases
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
8. North America Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     8.4.1. Circulating Call Free DNA (ccfDNA)
     8.4.2. Circulating Tumor Cells (CTCs)
     8.4.3. Exosomes/Extracellular Vesicles
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     8.7.1. NIPT
     8.7.2. Oncology
     8.7.3. Transcriptomics
     8.7.4. Pharmacogenomics
     8.7.5. Transplant Rejection
     8.7.6. Population Screening
     8.7.7. Cardiovascular
     8.7.8. Diseases
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
9. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     9.4.1. Circulating Call Free DNA (ccfDNA)
     9.4.2. Circulating Tumor Cells (CTCs)
     9.4.3. Exosomes/Extracellular Vesicles
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     9.7.1. NIPT
     9.7.2. Oncology
     9.7.3. Transcriptomics
     9.7.4. Pharmacogenomics
     9.7.5. Transplant Rejection
     9.7.6. Population Screening
     9.7.7. Cardiovascular
     9.7.8. Diseases
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
10. Europe Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     10.4.1. Circulating Call Free DNA (ccfDNA)
     10.4.2. Circulating Tumor Cells (CTCs)
     10.4.3. Exosomes/Extracellular Vesicles
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     10.7.1. NIPT
     10.7.2. Oncology
     10.7.3. Transcriptomics
     10.7.4. Pharmacogenomics
     10.7.5. Transplant Rejection
     10.7.6. Population Screening
     10.7.7. Cardiovascular
     10.7.8. Diseases
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
11. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     11.4.1. Circulating Call Free DNA (ccfDNA)
     11.4.2. Circulating Tumor Cells (CTCs)
     11.4.3. Exosomes/Extracellular Vesicles
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     11.7.1. NIPT
     11.7.2. Oncology
     11.7.3. Transcriptomics
     11.7.4. Pharmacogenomics
     11.7.5. Transplant Rejection
     11.7.6. Population Screening
     11.7.7. Cardiovascular
     11.7.8. Diseases
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
12. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
     12.4.1. Circulating Call Free DNA (ccfDNA)
     12.4.2. Circulating Tumor Cells (CTCs)
     12.4.3. Exosomes/Extracellular Vesicles
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
     12.7.1. NIPT
     12.7.2. Oncology
     12.7.3. Transcriptomics
     12.7.4. Pharmacogenomics
     12.7.5. Transplant Rejection
     12.7.6. Population Screening
     12.7.7. Cardiovascular
     12.7.8. Diseases
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Rare Biomarkers Specimen Collection and Stabilization Market: Market Share Analysis
  13.2. Rare Biomarkers Specimen Collection and Stabilization Distributors and Customers
  13.3. Rare Biomarkers Specimen Collection and Stabilization Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Advanced Cell Diagnostics, Inc.
     13.4.2. Agena Bioscience
     13.4.3. ANGLE plc.
     13.4.4. ApoCell, Inc.
     13.4.5. AS One InternationalNTERNATIONAL
     13.4.6. BioChain Institute, Inc.
     13.4.7. Biolidics Limited

Segments Covered in the Report:

By Product

  • Isolation Kits & Reagents
  • Blood Collection Tubes
  • Systems
By Types
  • Circulating Call Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Extracellular Vesicles
By Specimen
  • Serum/Plasma
  • Others
By Nucleic Acid & Other Biomolecules
  • RNA (Ribonucleic Acid)
  • DNA (Deoxyribonucleic Acid)
  • Others
By Application
  • NIPT
  • Oncology
  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Cardiovascular
  • Diseases
  • Others
By Regions
  • Asia Pacific
  • North America
  • Europe
  • Latin America
  • Middle East & Africa
By Key Players
  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc.
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pvt Ltd.
  • GILUPI GmbH

Some of the key players in the rare disease genetic testing market include Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc., ApoCell, Inc., AS One InternationalNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., Caltag Medsystems Limited, Cytomark Ltd., DNA Genotek, Inc., Epic Sciences, EpiGentek Group Inc., F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Geno Technology Inc., Genomax Technologies Pvt Ltd., and GILUPI GmbH.

Rare Biomarkers Specimen Collection and Stabilization Market by key players

Buy Report